Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Introduction: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after disease progression on atezolizumab-bevacizumab is unclear. Methods: This multinational, multicenter, and retrospecti...

Full description

Bibliographic Details
Main Authors: Changhoon Yoo, Jwa Hoon Kim, Min-Hee Ryu, Sook Ryun Park, Danbi Lee, Kang Mo Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Joycelyn Lee, David Tai, Stephen Lam Chan, Baek-Yeol Ryoo
Format: Article
Language:English
Published: Karger Publishers 2021-03-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
multikinase inhibitor
atezolizumab
bevacizumab
sorafenib
lenvatinib
Online Access:https://www.karger.com/Article/FullText/512781

Internet

https://www.karger.com/Article/FullText/512781

Similar Items